Stay updated on Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial
Sign up to get notified when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.

Latest updates to the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an updated version number from v2.16.0 to v2.16.1.SummaryDifference1.0%
- Check9 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.2%
- Check16 days agoChange DetectedThe page has removed a significant publication reference regarding the 4-year results of a phase 3 trial comparing adjuvant nivolumab and ipilimumab for melanoma, which is a core aspect of the content.SummaryDifference0.2%
- Check31 days agoChange DetectedThe page has been updated to reflect new data regarding the safety and tolerability of Nivolumab and Ipilimumab, with a significant increase in the duration of study from up to 60 months to up to 106.6 months. Additionally, the location has changed from Fridley, Minnesota to Robbinsdale, Minnesota.SummaryDifference1.0%
- Check45 days agoChange DetectedThe page has undergone significant content changes, including the removal of detailed study information regarding a clinical trial for melanoma and the addition of a new revision number and collaborators.SummaryDifference5%
- Check53 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
Stay in the know with updates to Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab vs Ipilimumab in Melanoma Recurrence Prevention Clinical Trial page.